Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approach  

作　　者：Leroy Lowe J.William LaValley Dean W.Felsher 

机构地区：[1]Getting to Know Cancer(NGO),Truro,Nova Scotia B2N 1X5,Canada [2]Wellness Plan MD Ltd,Austin,TX 78759,USA [3]Division of Oncology,Departments of Medicine and Pathology,Stanford University,CA CCSR 1105,USA.

出　　处：《Cancer Drug Resistance》2022年第4期917-925,共9页癌症耐药（英文）

摘　　要：Tumor heterogeneity can contribute to the development of therapeutic resistance in cancer, including advancedbreast cancers. The object of the Halifax project was to identify new treatments that would address mechanisms oftherapeutic resistance through tumor heterogeneity by uncovering combinations of therapeutics that could targetthe hallmarks of cancer rather than focusing on individual gene products. A taskforce of 180 cancer researchers,used molecular profiling to highlight key targets responsible for each of the hallmarks of cancer and then findexisting therapeutic agents that could be used to reach those targets with limited toxicity. In many cases, naturalhealth products and re-purposed pharmaceuticals were identified as potential agents. Hence, by combining themolecular profiling of tumors with therapeutics that target the hallmark features of cancer, the heterogeneity ofadvanced-stage breast cancers can be addressed.

关 键 词：Breast cancer CHEMORESISTANCE drug resistance targeted therapy 

分 类 号：R737.9[医药卫生—肿瘤]